Aridis signs exclusive terms to secure worldwide commercial licenses for pan-ebola and pan-marburg monoclonal antibody programs from mapp biopharmaceutical

Los gatos, calif., dec. 05, 2022 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-ebola and pan-marburg monoclonal antibody (mabs) programs from mapp biopharmaceutical, inc. (mappbio), a privately-owned leading developer of novel pharmaceuticals for the prevention and treatment of infectious diseases with a focus on unmet needs in global health and biodefense.
ARDS Ratings Summary
ARDS Quant Ranking